RxDoctor Payments Data

Eric Baron, DO

Neurology · Cleveland, OHNPI 1376719765

Payments from drug & device makers

$297,291in general payments, 2019–2025

Across 589 payments — averaging $504.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$92K
  • Biohaven Pharmaceuticals, Inc.$62K
  • Lundbeck LLC$54K
  • Impel Pharmaceuticals Inc.$39K
  • Biohaven Pharmaceutical Holding Company Ltd.$30K
  • Axsome Therapeutics, Inc.$12K
  • plus $9K from 9 others

What the payments were for

  • Consulting fees$29,19310%
  • Speaking & faculty fees$250,34784%
  • Travel & lodging$6,9802%
  • Food & beverage$10,6404%
  • Education$1320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$297,291 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$29,352
Medicare patients
178
Services billed
299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate143$197,220
QuliptaAtogepant140$164,959
UbrelvyUbrogepant58$104,192
Emgality PenGalcanezumab-Gnlm59$52,556
Aimovig AutoinjectorErenumab-Aooe54$47,427
Gabapentin349$5,069
Memantine Hcl29$3,687
Carbamazepine ErCarbamazepine42$2,994
Sumatriptan Succinate102$2,887
Oxcarbazepine35$2,292
Pregabalin54$2,046
RizatriptanRizatriptan Benzoate131$1,773
Naratriptan Hcl47$1,398
Topiramate90$915
Amitriptyline Hcl87$872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$92,091$269,151198 claims
PfizerNurtec Odt$8,062$197,220143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 702 neurology providers in Ohio.

Other neurology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →